Understanding how prostate cancer cells change to resist treatment
Novel Pathways in the Control of Lineage Plasticity in Neuroendocrine Prostate Cancer
This study is looking at why prostate cancer sometimes doesn't respond to treatments and how a protein called PKC might help fight a more aggressive type of the disease, with the goal of finding new ways to improve treatment for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10831970 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind the resistance of prostate cancer to current therapies, particularly focusing on how cancer cells can change their characteristics to survive despite treatment. It explores the role of a specific protein, PKC, which appears to act as a tumor suppressor in a more aggressive form of prostate cancer known as neuroendocrine prostate cancer (NEPC). By studying how the loss of this protein leads to changes in cancer cell behavior and metabolism, the research aims to identify new therapeutic targets that could improve treatment outcomes for patients. The approach includes analyzing patient samples and conducting laboratory experiments to understand these processes better.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced prostate cancer, particularly those who have developed resistance to androgen receptor-targeted therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively target resistant forms of prostate cancer, improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in cancer treatment, indicating that this approach could be effective.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Diaz Meco Conde, Maria Teresa — Weill Medical Coll of Cornell Univ
- Study coordinator: Diaz Meco Conde, Maria Teresa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.